Medical advancements over the last several decades have made great strides in the treatment of HIV. Pharmaceutical treatments ...
Wesley Sundquist, PhD, Samuels Professor and chair of biochemistry at the University of Utah, laid the foundation for the development of a highly effective, long-lasting prophylactic against HIV, ...
Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...
Forbes contributors publish independent expert analyses and insights. Dr. Omer Awan is a practicing physician who covers public health. A twice-yearly injection of a drug known as lenacapavir offered ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. We might be a step closer to curing HIV, as researchers have developed ...
There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...
The human immunodeficiency virus (HIV), which is the cause of AIDS, is a master of deception, using just nine genes to hijack the complex cellular machinery of the human body. Yet, even after decades ...
The human immunodeficiency virus (HIV), which is the cause of AIDS, is a master of deception, using just nine genes to hijack the complex cellular machinery of the human body. Yet, even after decades ...
A new study shows virus-like particle can effectively 'shock and kill' latent HIV reservoir in those living with chronic HIV. By 2030, the World Health Organization (WHO), the Global Fund and UNAIDS ...
Left: Structure of the Human Immunodeficiency Virus (HIV). Note the envelope protein that protects the virus against immunological detection and the small genome consisting of two short strands of RNA ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Before its headline-grabbing 100% efficacy rate in an HIV prevention trial and subsequent long-acting prophylactic approval, Gilead Sciences' lenacapavir was approved in 2022 as Sunlenca for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results